comparemela.com

Intj Clin Exp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs placebo in LAURA Phase III trial

WILMINGTON, Del. (BUSINESS WIRE) Jun 2, 2024

United statesUnited kingdomChelsea tresslerDaiichi sankyoBrendan mcevoyAmerican society of clinical oncologyWorld health organizationLungevity foundationLung ambition allianceInternational agency for research on cancerArchives pathology labSingle institution studyPlenary sessionClinical oncologyAnnual meetingNew england journal

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —

Hong kongUnited statesAtholl tweedieZhou yiBen atwellSingle institution studyAmerican cancer societyStock exchange of hong kongChina national medical products administrationExchange commissionEuropean lung cancer congress onEuropean lung cancer congressNational reimbursement drug listWorld health organizationChina limitedInternational agency for research on cancer

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients If.

Hong kongUnited statesBen atwellZhou yiAtholl tweedieChina limitedEuropean lung cancer congress onAmerican cancer societyNational reimbursement drug listStock exchange of hong kongEuropean lung cancer congressInternational agency for research on cancerWorld health organizationExchange commissionSingle institution studyChina national medical products administration

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting .

United statesUnited kingdomSuresh ramalingamSusan galbraithCerner cancermpactDaiichi sankyoInternational agency for research on cancerAmerican cancer societyLung ambition allianceWinship cancer institute of emory universityLungevity foundationSingle institution studyWorld health organisationExecutive directorWinship cancer instituteEmory university

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

WILMINGTON, Del. (BUSINESS WIRE) Oct 16, 2023

United kingdomUnited statesSusan galbraithBrendan mcevoyDaiichi sankyoChelsea fordWorld health organisationInternational agency for research on cancerLungevity foundationSingle institution studyLung ambition allianceDrug administrationNew drug applicationPriority reviewPrescription drug user fee actExecutive vice president

vimarsana © 2020. All Rights Reserved.